




























# Academic Concierge TAP Pipeline

TARGET THERAPY	INDICATION(S)	PRECLINICAL	PHASE I	PHASE II	PHASE III
<b>Cell Therapy</b> <i>MiLs</i>	<b>Multiple Myeloma</b>	 			
<b>Hedgehog</b> <i>PF-04449913</i>	<b>Acute Leukemias</b>	 			
<b>VDA</b> <i>OXi4503</i>	<b>AML/MDS</b>				
<b>CDA/DNMT1</b> <i>THU-Decitabine</i>	<b>AML/MDS</b>				
<b>Apoptosis</b> <i>Ciclopirox</i>	<b>Heme Malignancies</b>				
<b>CDC7</b> <i>MSK-777</i>	<b>Acute Leukemias</b>				
<b>BCL6</b> <i>RI-BPI</i>	<b>DLBCL</b>				
<b>Menin</b> <i>Sm Molecule</i>	<b>MLL Leukemias</b>	